12 results on '"Macaulay R"'
Search Results
2. PSY96 - FDA Orphan Exploitation? Are Pharma’s Approaches to Orphan Oncology Drug Approval Fuelling a Push for Reform By the FDA?
3. Fda Breakthrough Status Versus Accelerated Approval - What's the Difference?
4. How ready are european payers for ema adaptive pathways?
5. Could Giving Cost-Utility Hta Bodies Negotiating Powers Help Bridge The Gap between Cost-Containment and Broadening Coverage? A Systematic Review of all Swedish Nlt Appraisals of Hospital Pharmaceuticals.
6. Are the Irish Slower than they Think? A Systematic Analysis of all Recent Ncpe Appraisals.
7. PIN93 - Encouraging orphan designation for new ebola treatments – could this do more harm than good?
8. PHP31 - FDA breakthrough Therapy status - a systematic analysis of all Therapies approved under this new expedited Approval Pathway.
9. PCN156 - Factors affecting time required for PCODR decision making.
10. Approving Drugs Based on Early Stage Data - How Phase II Trial Data Correlates with Phase III Outcomes. Case Study: NSCLC.
11. The Cancer Drugs Fund: A Systematic Analysis of the Requirements For Inclusion on the English National List of Drugs for Priority Funding.
12. Comparing How Single Arm Phase II Trial Data Can Support Approval of Oncologics by European Health Technology Assessment Bodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.